Tatva Chintan Pharma Chem (BOM:543321) EBIT : ₹501 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tatva Chintan Pharma Chem EBIT?

Tatva Chintan Pharma Chem's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₹139 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹501 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tatva Chintan Pharma Chem's annualized ROC % for the quarter that ended in Mar. 2024 was 3.64%. Tatva Chintan Pharma Chem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tatva Chintan Pharma Chem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.97%.

Tatva Chintan Pharma Chem EBIT Historical Data

The historical data trend for Tatva Chintan Pharma Chem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tatva Chintan Pharma Chem EBIT Chart

Tatva Chintan Pharma Chem Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

513.49

646.81

1,084.72

531.83

501.00

Tatva Chintan Pharma Chem Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial												110.05	163.46	142.27	56.21	139.05

Competitive Comparison of Tatva Chintan Pharma Chem's EBIT

For the Specialty Chemicals subindustry, Tatva Chintan Pharma Chem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tatva Chintan Pharma Chem's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Tatva Chintan Pharma Chem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tatva Chintan Pharma Chem's EV-to-EBIT falls into.

Tatva Chintan Pharma Chem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹501 Mil.

Tatva Chintan Pharma Chem (BOM:543321) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tatva Chintan Pharma Chem's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	375.08 * ( 1 - 29.77% )	/	( (0	+	7246.42)	/ 1 )
=	263.418684	/	7246.42
=	3.64 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8187.18	-	450.31	-	( 490.45	-	max(0, 796.63	-	2979.06	+	490.45	))
=	7246.42

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Tatva Chintan Pharma Chem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	556.2	/	( ( (0 + max(0, 0))	+	(4994.62 + max(1825.89, 0)) )	/	1 )
=	556.2	/	( ( 0	+	6820.51 )	/	1 )
=	556.2	/	6820.51
=	8.15 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(698.52	+	1527.66	+	260.02)	-	(450.31	+	0	+	210)
=	1825.89

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tatva Chintan Pharma Chem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	500.99	/	25411.591
	=	1.97 %

Tatva Chintan Pharma Chem EBIT Related Terms

Thank you for viewing the detailed overview of Tatva Chintan Pharma Chem's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tatva Chintan Pharma Chem (BOM:543321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Tatva Chintan Pharma Chem Ltd (BOM:543321) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

TATVA:India

Address

Plot No. 353, Makarpura GIDC, Vadodara, GJ, IND, 390010

Website

https://www.tatvachintan.com

Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.

Tatva Chintan Pharma Chem (BOM:543321) Headlines

No Headlines